Saturday, October 31, 2026

EUR/CHF Bullish By 1% In The Last 10 Sessions

ViaNews Editorial Team

January 23, 2024

EUR/CHF Bullish By 1% In The Last 10 Sessions

(VIANEWS) - EUR/CHF (EURCHF) has been up by 1.16% for the last 10 sessions. At 17:06 EST on Tuesday, 23 January, EUR/CHF (EURCHF) is $0.94.

EUR/CHF's yearly highs and lows, it's 4.563% up from its 52-week low and 6.218% down from its 52-week high.

Volatility

EUR/CHF's last week, last month's, and last quarter's current intraday variation average was a positive 0.22%, a negative 0.01%, and a positive 0.25%, respectively.

EUR/CHF's highest amplitude of average volatility was 0.22% (last week), 0.23% (last month), and 0.25% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EUR/CHF's Forex is considered to be oversold (<=20).

News about

  • Eur/usd slightly dips below 1.0900 ahead of ecb’s decision. According to FXStreet on Monday, 22 January, "Although the EUR/USD headed south, it found support at the 200-day moving average (DMA) for two consecutive days in January 17 and 18, forming a 'tweezers bottom' chart pattern, that could open the door for further upside. "
  • Eur/usd drifts lower as markets gear up for central bank rate call week. According to FXStreet on Monday, 22 January, "The EUR/USD continues to trade into the south end of the 200-hour Simple Moving Average (SMA), slumping below the 1.0900 handle after a brief test above the barrier early Monday.", "The EUR/USD waffled on Monday, drifting down into the 1.0880 region as markets pivot ahead of a slew of central bank rate calls this week, with the European Central Bank (ECB) in particular focus for their monetary policy statement slated for Thursday."
  • Eur/usd tightens into the midrange as markets gear up for this week’s European pmis, ECB rate call. According to FXStreet on Monday, 22 January, "The EUR/USD continues to trade into a technical midrange between major moving averages as markets reach a shaky equilibrium between rate expectations and economic outlook between the Euro (EUR) and the US Dollar (USD). ", "The EUR/USD is shuffling its feet on Monday as traders take the opportunity to gather themselves up ahead of this week's hectic showing from multiple central banks across the globe."
  • Eur/usd lacks any firm near-term direction, oscillates in a range below 1.0900. According to FXStreet on Tuesday, 23 January, "The EUR/USD pair struggles to gain any meaningful traction during the Asian session on Tuesday and oscillates in a narrow trading band below the 1.0900 round-figure mark. ", "This, along with the mixed fundamental backdrop, should help limit the downside for the EUR/USD pair ahead of this week's key central bank event risk and important macro data. "
  • Eur/usd price analysis: hovers above 1.0900 followed by the 23.6% fibonacci level. According to FXStreet on Monday, 22 January, "Additionally, the trend-following momentum indicator suggests a confirmation of the bearish trend in the EUR/USD pair as the "Moving Average Convergence Divergence (MACD)" line lies below the centreline and shows a divergence below the signal line.", "The EUR/USD pair receives upward support on an improved risk appetite sentiment ahead of the European Central Bank's (ECB) January monetary policy meeting scheduled to be released on Thursday."

More news about EUR/CHF (EURCHF).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com